BIOINVISION INC — Department of Health and Human Services SBIR Phase II: 102

Description

Cancer Imaging and Therapy Analysis PlatformCITAPSummary We will create a preclinicalquantitativeCancer Imaging and Therapy Analysis PlatformCITAPpronounced sea tapwhich will allow one to study cancer biology and optimize pipelines of technologiesimaging agentsimaging methodstargeted nano therapeuticsimmunotherapytumor modelsetcespecially for metastatic and invasive cancersTodayprimary tumor masses are clinically controlled with surgicaldrugand radiation therapiesbut the ability to control metastatic cancer is limited and patients most often die from metastasesArguablymetastatic cancer is the most important front in the war on cancerbut it is hampered by an inability to see the enemyPreclinical research on micro metastasescell tommand largerscattered throughout the body is challenging because histology is impractical and because traditional in vivo imaging has insufficient resolution and contrast for reliable detectionCITAP will provide uniquequantitative assessments for optimization of technologies targeting metastatic and invasive cancersThe central technology will be cryo imaginga section and image technique which provides anatomical color and molecular fluorescencesingle cell sensitivityD microscopic imaging over vast volumesas large as an entire mouseThis will be linked via registration software to small animal medical imaging modalitiesPETMRISPECTfluorescenceultrasoundetcand to histologyThe platform will include experimental methodssmall animal imagingcryo imaginghistologyand softwareglueWith visualization softwarea researcher will zoom to a small GFP labeled tumordetermine the presence of imaging agent using highly sensitive cryo fluorescencedetermine if there is detectable MR signaland optionally examine histology for target moleculesSoftware will also provide unique quantitative analyses of tumor burdenincluding micro metastasesheterogeneous tumorand dispersing tumor cellsproviding unique assessments of therapeuticsCITAP will add significant value to BioInVision s product line by providing a quantitative platform for assessments and optimization of cancer technologies Project NarrativeAlthough a primary tumor mass can be controlledthe ability to control metastatic cancer is limited and patients most often die from metastasesWe will create a uniquepreclinicalquantitative Cancer Imaging and Therapy Analysis PlatformCITAPsuitable for the evaluation and optimization of pipelines of technologiesimaging agentsimaging methodstherapeuticstumor modelsetcimportant for detectingunderstandingand treating metastatic and invasive cancers